STEPHEN K TYRING
- Type
- Physician · Allopathic & Osteopathic Physicians / Dermatology
- Where
- WEBSTER, TX
- NPI
- 1245227263
- Received
- $1,162,216 in 2,099 records, 2019 to 2025 ($879,553 general, $282,663 research)
- As principal investigator
- $12,320,331 of research payments to others in 2,415 records
- Person page
- STEPHEN K TYRING Fuzzy (full name with a middle part, and the recipient's state)
- Source
- CMS Open Payments search ↗
On this site
- Person page: Stephen K Tyring Fuzzy (same full name with a middle name or initial, one person page, in that person's states)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 327 | $106,392 |
| 2025 | Research payment | 10 | $1,403 |
| 2024 | General payment | 348 | $114,279 |
| 2024 | Research payment | 8 | $7,646 |
| 2023 | General payment | 291 | $130,184 |
| 2023 | Research payment | 6 | $10,671 |
| 2022 | General payment | 308 | $149,479 |
| 2022 | Research payment | 8 | $28,666 |
| 2021 | General payment | 242 | $126,489 |
| 2021 | Research payment | 14 | $46,588 |
| 2020 | General payment | 142 | $95,497 |
| 2020 | Research payment | 57 | $103,483 |
| 2019 | General payment | 271 | $157,231 |
| 2019 | Research payment | 67 | $84,203 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 219 | $579,341 |
| Research payment | 170 | $282,663 |
| Consulting Fee | 48 | $149,582 |
| Honoraria | 26 | $67,360 |
| Food and Beverage | 1,429 | $46,492 |
| Travel and Lodging | 196 | $36,321 |
| Education | 11 | $455 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | Regeneron Pharmaceuticals, Inc. | $49 | Research payment | In-kind items and services | LIBTAYO Biological, ONCOLOGY | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous | 2025 |
| 2025-12-31 | Regeneron Pharmaceuticals, Inc. | $25 | Research payment | In-kind items and services | LIBTAYO Biological, ONCOLOGY | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous | 2025 |
| 2025-12-31 | Regeneron Pharmaceuticals, Inc. | $17 | Research payment | In-kind items and services | LIBTAYO Biological, ONCOLOGY | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous | 2025 |
| 2025-12-23 | Mallinckrodt Hospital Products Inc. | $24 | Food and Beverage | In-kind items and services | ACTHAR Biological, IMMUNOLOGY | 2025 | |
| 2025-12-22 | ABBVIE INC. | $15 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-12-19 | Mallinckrodt Hospital Products Inc. | $15 | Food and Beverage | In-kind items and services | ACTHAR Biological, IMMUNOLOGY | 2025 | |
| 2025-12-19 | Regeneron Healthcare Solutions, Inc. | $14 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-12-19 | ABBVIE INC. | $11 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-12-19 | SUN PHARMACEUTICAL INDUSTRIES INC. | $2 | Food and Beverage | In-kind items and services | Leqselvi Biological, Dermatology | 2025 | |
| 2025-12-17 | PFIZER INC. | $5 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-12-15 | Janssen Biotech, Inc. | $7 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-12-12 | Regeneron Healthcare Solutions, Inc. | $13 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-12-12 | Galderma Laboratories, L.P. | $7 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | $506 | Research payment | In-kind items and services | LIBTAYO Biological, ONCOLOGY | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | $105 | Research payment | In-kind items and services | LIBTAYO Biological, ONCOLOGY | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | $87 | Research payment | In-kind items and services | LIBTAYO Biological, ONCOLOGY | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | $76 | Research payment | In-kind items and services | LIBTAYO Biological, ONCOLOGY | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | $55 | Research payment | In-kind items and services | LIBTAYO Biological, ONCOLOGY | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous | 2025 |
| 2025-12-11 | Regeneron Pharmaceuticals, Inc. | $30 | Research payment | In-kind items and services | LIBTAYO Biological, ONCOLOGY | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous | 2025 |
| 2025-12-08 | Janssen Pharmaceuticals, Inc | $13 | Education | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-12-08 | Janssen Biotech, Inc. | $6 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-12-08 | PFIZER INC. | $4 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-12-05 | PFIZER INC. | $4 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-11-25 | PFIZER INC. | $3 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-11-19 | Regeneron Pharmaceuticals, Inc. | $449 | Research payment | In-kind items and services | LIBTAYO Biological, ONCOLOGY | A Phase 3 Randomized Study of Intralesional Cemiplimab Versus Primary Surgery in Participants With Early Stage Cutaneous | 2025 |
| 2025-11-19 | ABBVIE INC. | $7 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-11-18 | Novartis Pharmaceuticals Corporation | $126 | Food and Beverage | In-kind items and services | Rhapsido Drug, Immunology | 2025 | |
| 2025-11-18 | Galderma Laboratories, L.P. | $13 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-11-18 | Galderma Laboratories, L.P. | $6 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-11-17 | Janssen Biotech, Inc. | $35 | Travel and Lodging | Cash or cash equivalent | TREMFYA Drug, Immunology | 2025 | |
| 2025-11-17 | Galderma Laboratories, L.P. | $4 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-11-15 | Janssen Biotech, Inc. | $4,050 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TREMFYA Drug, Immunology | 2025 | |
| 2025-11-14 | Galderma Laboratories, L.P. | $3,600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-11-14 | LEO Pharma Inc. | $1 | Food and Beverage | In-kind items and services | ADBRY Biological, DERMATOLOGY | 2025 | |
| 2025-11-13 | Janssen Biotech, Inc. | $107 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-11-13 | Regeneron Healthcare Solutions, Inc. | $13 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-11-12 | ABBVIE INC. | $9 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-11-06 | Galderma Laboratories, L.P. | $124 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-10-31 | GENZYME CORPORATION | $17 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-10-30 | Mallinckrodt Hospital Products Inc. | $21 | Food and Beverage | In-kind items and services | ACTHAR Biological, IMMUNOLOGY | 2025 | |
| 2025-10-30 | Teva Pharmaceuticals USA, Inc. | $17 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-22 | LEO Pharma Inc. | $3 | Food and Beverage | In-kind items and services | ADBRY Biological, DERMATOLOGY | 2025 | |
| 2025-10-09 | Regeneron Healthcare Solutions, Inc. | $16 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-10-09 | ABBVIE INC. | $16 | Food and Beverage | In-kind items and services | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-10-06 | PFIZER INC. | $5 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-10-03 | Takeda Pharmaceuticals U.S.A., Inc. | $84 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-10-03 | SUN PHARMACEUTICAL INDUSTRIES INC. | $10 | Food and Beverage | In-kind items and services | Winlevi Drug, Dermatology | 2025 | |
| 2025-10-03 | PFIZER INC. | $5 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-10-02 | LEO Pharma Inc. | $62 | Food and Beverage | In-kind items and services | ANZUPGO Drug, DERMATOLOGY | 2025 | |
| 2025-10-02 | Paratek Pharmaceuticals, Inc. | $14 | Food and Beverage | In-kind items and services | NUZYRA Drug, ANTIBIOTIC | 2025 | |
| 2025-10-02 | PFIZER INC. | $5 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-10-01 | LEO Pharma Inc. | $2 | Food and Beverage | In-kind items and services | ADBRY Biological, DERMATOLOGY | 2025 | |
| 2025-09-30 | Galderma Laboratories, L.P. | $18 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-09-29 | GENZYME CORPORATION | $28 | Food and Beverage | In-kind items and services | AYVAKIT Biological, Gastroenterology | 2025 | |
| 2025-09-26 | GENZYME CORPORATION | $17 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-09-26 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-09-22 | Arcutis Biotherapeutics, Inc. | $11 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-09-19 | UCB, Inc. | $150 | Food and Beverage | In-kind items and services | Bimzelx Biological, Immunology | 2025 | |
| 2025-09-19 | Organon Llc | $23 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-19 | Janssen Biotech, Inc. | $11 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-09-19 | PFIZER INC. | $4 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-09-18 | PFIZER INC. | $7 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-09-18 | PFIZER INC. | $5 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-09-17 | Galderma Laboratories, L.P. | $21 | Food and Beverage | In-kind items and services | AKLIEF Drug, ACNE | 2025 | |
| 2025-09-17 | LEO Pharma Inc. | $4 | Food and Beverage | In-kind items and services | ADBRY Biological, DERMATOLOGY | 2025 | |
| 2025-09-16 | REVANCE THERAPEUTICS, INC. | $47 | Food and Beverage | In-kind items and services | DAXI Drug, AESTHETICS AND THERAPEUTICS | 2025 | |
| 2025-09-15 | ABBVIE INC. | $21 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-09-15 | Janssen Biotech, Inc. | $11 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-09-12 | Arcutis Biotherapeutics, Inc. | $25 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-09-12 | GENZYME CORPORATION | $15 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-09-12 | PFIZER INC. | $7 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-09-11 | PFIZER INC. | $119 | Food and Beverage | In-kind items and services | LITFULO Drug, IMMUNOLOGY | 2025 | |
| 2025-09-11 | Organon Llc | $9 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-10 | Arcutis Biotherapeutics, Inc. | $3 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-09-09 | MAYNE PHARMA COMMERCIAL LLC | $12 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-08 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-09-08 | Janssen Biotech, Inc. | $11 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-09-08 | PFIZER INC. | $4 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-09-06 | Galderma Laboratories, L.P. | $5,460 | Consulting Fee | Cash or cash equivalent | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-09-06 | Galderma Laboratories, L.P. | $91 | Travel and Lodging | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-09-05 | Janssen Biotech, Inc. | $12 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-09-04 | Incyte Corporation | $26 | Food and Beverage | Cash or cash equivalent | OPZELURA Drug, Dermatology | 2025 | |
| 2025-09-04 | PFIZER INC. | $4 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-09-03 | Organon Llc | $25 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-09-03 | Arcutis Biotherapeutics, Inc. | $7 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-08-30 | Janssen Scientific Affairs, LLC | $149 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-08-29 | Galderma Laboratories, L.P. | $9 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-08-28 | Mallinckrodt Hospital Products Inc. | $7 | Food and Beverage | In-kind items and services | ACTHAR Biological, IMMUNOLOGY | 2025 | |
| 2025-08-28 | Mallinckrodt Hospital Products Inc. | $6 | Food and Beverage | In-kind items and services | ACTHAR Biological, IMMUNOLOGY | 2025 | |
| 2025-08-28 | PFIZER INC. | $6 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-08-28 | Mallinckrodt Hospital Products Inc. | $0 | Food and Beverage | In-kind items and services | ACTHAR Biological, IMMUNOLOGY | 2025 | |
| 2025-08-26 | Galderma Laboratories, L.P. | $145 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-08-25 | GlaxoSmithKline, LLC. | $650 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SHINGRIX Biological, VACCINES | 2025 | |
| 2025-08-25 | Arcutis Biotherapeutics, Inc. | $14 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-08-25 | Regeneron Healthcare Solutions, Inc. | $14 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-08-25 | PFIZER INC. | $5 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-08-22 | ABBVIE INC. | $20 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-08-21 | Amgen Inc. | $17 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-08-20 | ABBVIE INC. | $18 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-08-14 | Galderma Laboratories, L.P. | $19 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-08-14 | GENZYME CORPORATION | $13 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-08-12 | Janssen Biotech, Inc. | $1,800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TREMFYA Drug, Immunology | 2025 | |
| 2025-08-11 | Janssen Biotech, Inc. | $12 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-08-08 | Arcutis Biotherapeutics, Inc. | $8 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-08-08 | PFIZER INC. | $5 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-08-06 | ABBVIE INC. | $2,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-08-04 | GENZYME CORPORATION | $21 | Food and Beverage | In-kind items and services | AYVAKIT Biological, Gastroenterology | 2025 | |
| 2025-08-01 | Galderma Laboratories, L.P. | $600 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-08-01 | Janssen Biotech, Inc. | $12 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-07-31 | GENZYME CORPORATION | $14 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-07-31 | Arcutis Biotherapeutics, Inc. | $11 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-07-28 | Galderma Laboratories, L.P. | $14 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-07-28 | Janssen Biotech, Inc. | $6 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-07-28 | PFIZER INC. | $6 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-07-26 | Janssen Biotech, Inc. | $1,350 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TREMFYA Drug, Immunology | 2025 | |
| 2025-07-25 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-07-25 | Janssen Biotech, Inc. | $9 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-07-25 | PFIZER INC. | $4 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-07-23 | Galderma Laboratories, L.P. | $7 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-07-23 | ABBVIE INC. | $2 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-07-22 | Mallinckrodt Hospital Products Inc. | $103 | Food and Beverage | In-kind items and services | ACTHAR Biological, IMMUNOLOGY | 2025 | |
| 2025-07-22 | ABBVIE INC. | $19 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-07-19 | Janssen Biotech, Inc. | $1,800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TREMFYA Drug, Immunology | 2025 | |
| 2025-07-18 | Regeneron Healthcare Solutions, Inc. | $99 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-07-18 | Janssen Biotech, Inc. | $9 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-07-17 | GENZYME CORPORATION | $14 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-07-16 | GlaxoSmithKline, LLC. | $3,900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SHINGRIX Biological, VACCINES | 2025 | |
| 2025-07-14 | GlaxoSmithKline, LLC. | $67 | Travel and Lodging | Cash or cash equivalent | SHINGRIX Biological, VACCINES | 2025 | |
| 2025-07-14 | PFIZER INC. | $5 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-07-14 | GlaxoSmithKline, LLC. | $4 | Food and Beverage | Cash or cash equivalent | SHINGRIX Biological, VACCINES | 2025 | |
| 2025-07-11 | PFIZER INC. | $4 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-07-10 | Mallinckrodt Hospital Products Inc. | $64 | Food and Beverage | In-kind items and services | ACTHAR Biological, IMMUNOLOGY | 2025 | |
| 2025-07-09 | LEO Pharma Inc. | $128 | Food and Beverage | In-kind items and services | ANZUPGO Drug, DERMATOLOGY | 2025 | |
| 2025-07-09 | Mallinckrodt Hospital Products Inc. | $19 | Food and Beverage | In-kind items and services | ACTHAR Biological, IMMUNOLOGY | 2025 | |
| 2025-07-09 | PFIZER INC. | $6 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-07-09 | Mallinckrodt Hospital Products Inc. | $1 | Food and Beverage | In-kind items and services | ACTHAR Biological, IMMUNOLOGY | 2025 | |
| 2025-07-08 | Regeneron Healthcare Solutions, Inc. | $12 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-07-08 | Mallinckrodt Hospital Products Inc. | $0 | Food and Beverage | In-kind items and services | ACTHAR Biological, IMMUNOLOGY | 2025 | |
| 2025-07-07 | ABBVIE INC. | $4,900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-07-07 | Janssen Scientific Affairs, LLC | $149 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-07-03 | Regeneron Healthcare Solutions, Inc. | $14 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-07-02 | ConvaTec Inc. | $37 | Food and Beverage | In-kind items and services | INNOVAMATRIX AC Device, ADVANCED WOUND CARE | 2025 | |
| 2025-06-27 | PFIZER INC. | $4 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-06-26 | GlaxoSmithKline, LLC. | $1,582 | Travel and Lodging | In-kind items and services | SHINGRIX Biological, VACCINES | 2025 | |
| 2025-06-26 | GlaxoSmithKline, LLC. | $209 | Travel and Lodging | In-kind items and services | SHINGRIX Biological, VACCINES | 2025 | |
| 2025-06-26 | GlaxoSmithKline, LLC. | $108 | Food and Beverage | In-kind items and services | SHINGRIX Biological, VACCINES | 2025 | |
| 2025-06-24 | GENZYME CORPORATION | $113 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-06-24 | Janssen Biotech, Inc. | $11 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-06-23 | GENZYME CORPORATION | $15 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-06-18 | ABBVIE INC. | $13 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-06-18 | PFIZER INC. | $8 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-06-17 | Mallinckrodt Hospital Products Inc. | $14 | Food and Beverage | In-kind items and services | ACTHAR Biological, IMMUNOLOGY | 2025 | |
| 2025-06-16 | ABBVIE INC. | $2,100 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | 2025 | |
| 2025-06-16 | Janssen Biotech, Inc. | $12 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-06-16 | Mallinckrodt Hospital Products Inc. | $0 | Food and Beverage | In-kind items and services | ACTHAR Biological, IMMUNOLOGY | 2025 | |
| 2025-06-13 | GENZYME CORPORATION | $14 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-06-12 | STRATA Skin Sciences, Inc. | $105 | Food and Beverage | In-kind items and services | XTRAC Device, Dermatology | 2025 | |
| 2025-06-12 | PFIZER INC. | $6 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-06-12 | PFIZER INC. | $4 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-06-10 | ABBVIE INC. | $601 | Travel and Lodging | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-06-10 | ABBVIE INC. | $108 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-06-09 | ABBVIE INC. | $31 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-06-05 | Regeneron Healthcare Solutions, Inc. | $18 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-06-04 | ConvaTec Inc. | $32 | Food and Beverage | In-kind items and services | INNOVAMATRIX AC Device, ADVANCED WOUND CARE | 2025 | |
| 2025-06-03 | Janssen Biotech, Inc. | $13 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-05-31 | Janssen Biotech, Inc. | $4,050 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TREMFYA Drug, Immunology | 2025 | |
| 2025-05-30 | ABBVIE INC. | $17 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-05-30 | PFIZER INC. | $4 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-05-27 | Almirall LLC | $930 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-05-27 | Arcutis Biotherapeutics, Inc. | $20 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-05-27 | GENZYME CORPORATION | $14 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-05-23 | Janssen Biotech, Inc. | $9 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-05-21 | Galderma Laboratories, L.P. | $9 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-05-21 | PFIZER INC. | $5 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-05-20 | ABBVIE INC. | $3,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-05-20 | Regeneron Healthcare Solutions, Inc. | $16 | Food and Beverage | In-kind items and services | DUPIXENT Biological, IMMUNOLOGY AND INFLAMMATION | 2025 | |
| 2025-05-19 | Janssen Biotech, Inc. | $99 | Education | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-05-19 | Janssen Biotech, Inc. | $10 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-05-14 | GENZYME CORPORATION | $18 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-05-14 | PFIZER INC. | $4 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-05-13 | Janssen Biotech, Inc. | $10 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-05-13 | Arcutis Biotherapeutics, Inc. | $3 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 | |
| 2025-05-12 | ABBVIE INC. | $4,900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-05-12 | ABBVIE INC. | $4,900 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-05-10 | Janssen Biotech, Inc. | $1,800 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | TREMFYA Drug, Immunology | 2025 | |
| 2025-05-09 | PFIZER INC. | $4,275 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | LITFULO Drug, IMMUNOLOGY | 2025 | |
| 2025-05-08 | PFIZER INC. | $30 | Travel and Lodging | In-kind items and services | LITFULO Drug, IMMUNOLOGY | 2025 | |
| 2025-05-07 | PFIZER INC. | $108 | Food and Beverage | In-kind items and services | LITFULO Drug, IMMUNOLOGY | 2025 | |
| 2025-05-07 | PFIZER INC. | $2 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-05-06 | Galderma Laboratories, L.P. | $15 | Food and Beverage | In-kind items and services | NEMLUVIO Drug, DERMATITIS | 2025 | |
| 2025-05-05 | Journey Medical Corporation | $115 | Food and Beverage | In-kind items and services | 2025 | ||
| 2025-05-02 | Janssen Biotech, Inc. | $12 | Food and Beverage | In-kind items and services | TREMFYA Drug, Immunology | 2025 | |
| 2025-05-02 | PFIZER INC. | $3 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-05-01 | Mallinckrodt Hospital Products Inc. | $17 | Food and Beverage | In-kind items and services | ACTHAR Biological, IMMUNOLOGY | 2025 | |
| 2025-04-30 | Amgen Inc. | $21 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-04-29 | GENZYME CORPORATION | $14 | Food and Beverage | In-kind items and services | DUPIXENT Biological, Immunology | 2025 | |
| 2025-04-29 | PFIZER INC. | $9 | Food and Beverage | In-kind items and services | CIBINQO Drug, Inflammation & Immunology | 2025 | |
| 2025-04-25 | Amgen Inc. | $27 | Food and Beverage | In-kind items and services | OTEZLA Drug, Inflammation | 2025 | |
| 2025-04-24 | ABBVIE INC. | $125 | Food and Beverage | In-kind items and services | RINVOQ Biological, IMMUNOLOGY | 2025 | |
| 2025-04-24 | Arcutis Biotherapeutics, Inc. | $12 | Food and Beverage | In-kind items and services | Zoryve Drug, Dermatology | 2025 |
The latest 200 records of 2,099.
Research payments naming this person as principal investigator
| Date | Company | Paid to | Amount | Study | Year |
|---|---|---|---|---|---|
| 2025-12-31 | ABBVIE INC. | CENTER FOR CLINICAL STUDIES LTD LLP | $1,529 | A Phase 3 randomized, placebo-controlled, double-blind program to evaluate efficacy and safety of upadacitinib in adult | 2025 |
| 2025-12-31 | ABBVIE INC. | CENTER FOR CLINICAL STUDIES LTD LLP | $665 | A Phase 4 Multicenter, Randomized, Double-Blind Study of Risankizumab for the Treatment of Adult Subjects with Moderate | 2025 |
| 2025-12-29 | Janssen Research & Development, LLC | CENTER FOR CLINICAL STUDIES LTD LLP | $11,808 | A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Ef | 2025 |
| 2025-12-22 | SANOFI PASTEUR INC. | CENTER FOR CLINICAL STUDIES LTD LLP | $1,316 | A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunog | 2025 |
| 2025-12-19 | Janssen Research & Development, LLC | CENTER FOR CLINICAL STUDIES LTD LLP | $1,601 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Stu | 2025 |
| 2025-12-18 | SUN PHARMACEUTICAL INDUSTRIES INC. | CENTER FOR CLINICAL STUDIES LTD LLP | $3,374 | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Ps | 2025 |
| 2025-12-17 | PFIZER INC. | CENTER FOR CLINICAL STUDIES LTD LLP | $1,902 | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY | 2025 |
| 2025-12-17 | PFIZER INC. | Center for Clinical Studies LTDLLP | $1,103 | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD W | 2025 |
| 2025-12-17 | ABBVIE INC. | CENTER FOR CLINICAL STUDIES LTD LLP | $641 | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Sc | 2025 |
| 2025-12-17 | ABBVIE INC. | CENTER FOR CLINICAL STUDIES LTD LLP | $906 | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Sc | 2025 |
| 2025-12-15 | Janssen Research & Development, LLC | CENTER FOR CLINICAL STUDIES LTD LLP | $25 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-772 | 2025 |
| 2025-12-11 | PFIZER INC. | CENTER FOR CLINICAL STUDIES LTD LLP | $4,546 | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY | 2025 |
| 2025-12-08 | SANOFI US SERVICES INC. | CENTER FOR CLINICAL STUDIES LTD LLP | $5,078 | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evalu | 2025 |
| 2025-12-04 | Incyte Corporation | CENTER FOR CLINICAL STUDIES | $1,200 | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | 2025 |
| 2025-12-04 | Incyte Corporation | CENTER FOR CLINICAL STUDIES | $1,631 | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | 2025 |
| 2025-12-04 | Incyte Corporation | CENTER FOR CLINICAL STUDIES | $3,855 | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participa | 2025 |
| 2025-12-04 | SUN PHARMACEUTICAL INDUSTRIES INC. | CENTER FOR CLINICAL STUDIES LTD LLP | $750 | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Ps | 2025 |
| 2025-12-04 | SUN PHARMACEUTICAL INDUSTRIES INC. | CENTER FOR CLINICAL STUDIES LTD LLP | $2,377 | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Ps | 2025 |
| 2025-12-04 | ABBVIE INC. | CENTER FOR CLINICAL STUDIES LTD LLP | $6,846 | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Sever | 2025 |
| 2025-12-04 | ABBVIE INC. | CENTER FOR CLINICAL STUDIES LTD LLP | $1,594 | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Sever | 2025 |
| 2025-12-04 | ABBVIE INC. | CENTER FOR CLINICAL STUDIES LTD LLP | $5,130 | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participant | 2025 |
| 2025-12-04 | Incyte Corporation | CENTER FOR CLINICAL STUDIES | $3,398 | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participa | 2025 |
| 2025-12-04 | ABBVIE INC. | CENTER FOR CLINICAL STUDIES LTD LLP | $1,890 | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Mode | 2025 |
| 2025-12-03 | PFIZER INC. | Center for Clinical Studies LTDLLP | $1,103 | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD W | 2025 |
| 2025-12-02 | Boehringer Ingelheim Pharmaceuticals, Inc. | CENTER FOR CLINICAL STUDIES | $600 | Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolima | 2025 |
| 2025-12-01 | Janssen Research & Development, LLC | CENTER FOR CLINICAL STUDIES LTD LLP | $94 | A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Ef | 2025 |
| 2025-11-26 | PFIZER INC. | Center for Clinical Studies LTDLLP | $2,206 | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD W | 2025 |
| 2025-11-25 | Incyte Corporation | CENTER FOR CLINICAL STUDIES | $3,500 | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | 2025 |
| 2025-11-25 | Incyte Corporation | CENTER FOR CLINICAL STUDIES | $999 | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | 2025 |
| 2025-11-20 | Incyte Corporation | CENTER FOR CLINICAL STUDIES | $6,600 | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | 2025 |
| 2025-11-20 | Incyte Corporation | CENTER FOR CLINICAL STUDIES | $90 | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | 2025 |
| 2025-11-20 | Incyte Corporation | CENTER FOR CLINICAL STUDIES | $537 | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | 2025 |
| 2025-11-20 | Incyte Corporation | CENTER FOR CLINICAL STUDIES | $725 | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | 2025 |
| 2025-11-20 | Regeneron Pharmaceuticals, Inc. | CENTER FOR CLINICAL STUDIES LTD LLP | $2,200 | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPI | 2025 |
| 2025-11-20 | Regeneron Pharmaceuticals, Inc. | CENTER FOR CLINICAL STUDIES LTD LLP | $1,500 | AN OPEN-LABEL SINGLE-ARM STUDY OF DUPILUMAB IN ADOLESCENT AND ADULT SKIN OF COLOR PATIENTS WITH MODERATE-TO-SEVERE ATOPI | 2025 |
| 2025-11-20 | Incyte Corporation | CENTER FOR CLINICAL STUDIES | $352 | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | 2025 |
| 2025-11-17 | Incyte Corporation | CENTER FOR CLINICAL STUDIES WEBSTER | $238 | A study to evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis | 2025 |
| 2025-11-17 | E.R. Squibb & Sons, L.L.C. | CENTER FOR CLINICAL STUDIES | $28,848 | A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinuma | 2025 |
| 2025-11-14 | SANOFI PASTEUR INC. | CENTER FOR CLINICAL STUDIES LTD LLP | $4,566 | A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunog | 2025 |
| 2025-11-14 | Incyte Corporation | CENTER FOR CLINICAL STUDIES | $281 | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participa | 2025 |
| 2025-11-13 | SUN PHARMACEUTICAL INDUSTRIES INC. | CENTER FOR CLINICAL STUDIES LTD LLP | $9,770 | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Ps | 2025 |
| 2025-11-07 | Incyte Corporation | CENTER FOR CLINICAL STUDIES | $1,250 | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participa | 2025 |
| 2025-11-07 | Incyte Corporation | CENTER FOR CLINICAL STUDIES | $982 | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participa | 2025 |
| 2025-11-07 | Incyte Corporation | CENTER FOR CLINICAL STUDIES | $180 | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participa | 2025 |
| 2025-11-07 | Incyte Corporation | CENTER FOR CLINICAL STUDIES | $6,600 | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participa | 2025 |
| 2025-11-07 | Incyte Corporation | CENTER FOR CLINICAL STUDIES | $630 | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participa | 2025 |
| 2025-11-07 | Incyte Corporation | CENTER FOR CLINICAL STUDIES | $490 | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participa | 2025 |
| 2025-11-07 | ABBVIE INC. | CENTER FOR CLINICAL STUDIES LTD LLP | $377 | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participant | 2025 |
| 2025-11-05 | ABBVIE INC. | CENTER FOR CLINICAL STUDIES LTD LLP | $13,141 | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Sever | 2025 |
| 2025-11-04 | ABBVIE INC. | CENTER FOR CLINICAL STUDIES LTD LLP | $3,215 | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Sc | 2025 |
| 2025-11-04 | ABBVIE INC. | CENTER FOR CLINICAL STUDIES LTD LLP | $6,938 | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participant | 2025 |
| 2025-11-03 | Janssen Research & Development, LLC | CENTER FOR CLINICAL STUDIES LTD LLP | $6,504 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study t | 2025 |
| 2025-11-03 | Janssen Research & Development, LLC | CENTER FOR CLINICAL STUDIES LTD LLP | $16,853 | A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Ef | 2025 |
| 2025-11-03 | Janssen Research & Development, LLC | CENTER FOR CLINICAL STUDIES LTD LLP | $1,262 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Stu | 2025 |
| 2025-10-31 | SANOFI PASTEUR INC. | CENTER FOR CLINICAL STUDIES LTD LLP | $4,261 | A Phase I/II, Randomized, Placebo-controlled, Multi-arm, Dose-finding Study to Evaluate the Safety, Efficacy and Immunog | 2025 |
| 2025-10-31 | Janssen Research & Development, LLC | CENTER FOR CLINICAL STUDIES LTD LLP | $1,601 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-772 | 2025 |
| 2025-10-30 | ABBVIE INC. | CENTER FOR CLINICAL STUDIES LTD LLP | $3,372 | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participant | 2025 |
| 2025-10-30 | ABBVIE INC. | CENTER FOR CLINICAL STUDIES LTD LLP | $900 | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Sever | 2025 |
| 2025-10-29 | ABBVIE INC. | CENTER FOR CLINICAL STUDIES LTD LLP | $3,270 | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Sever | 2025 |
| 2025-10-29 | PFIZER INC. | Center for Clinical Studies LTDLLP | $1,332 | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD W | 2025 |
| 2025-10-28 | Novartis Pharmaceuticals Corporation | CENTER FOR CLINICAL STUDIES | $2,207 | A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase II Platform Study to Assess the Efficacy and Safety o | 2025 |
| 2025-10-27 | Teva Pharmaceuticals USA, Inc. | Center for Clinical Studies, LTD, LLP | $13,145 | A Phase 1b, Open-Label Trial to Assess Safety and Exploratory Efficacy of TEV-53408 in Participants With Vitiligo | 2025 |
| 2025-10-23 | SUN PHARMACEUTICAL INDUSTRIES INC. | CENTER FOR CLINICAL STUDIES LTD LLP | $4,823 | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Ps | 2025 |
| 2025-10-23 | Incyte Corporation | CENTER FOR CLINICAL STUDIES | $909 | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participa | 2025 |
| 2025-10-22 | PFIZER INC. | Center for Clinical Studies LTDLLP | $1,332 | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD W | 2025 |
| 2025-10-22 | Incyte Corporation | CENTER FOR CLINICAL STUDIES | $6,877 | A Phase 3, Double-Blinded, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participant | 2025 |
| 2025-10-20 | Eli Lilly and Company | CENTER FOR CLINICAL STUDIES LTD LLP | $5,344 | A STUDY OF LY3972406 IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | 2025 |
| 2025-10-17 | Janssen Research & Development, LLC | CENTER FOR CLINICAL STUDIES LTD LLP | $3,000 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study t | 2025 |
| 2025-10-14 | SANOFI US SERVICES INC. | CENTER FOR CLINICAL STUDIES LTD LLP | $1,999 | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallelgroup, 3-arm, Multinational, Multicenter Study to Evalu | 2025 |
| 2025-10-14 | Eli Lilly and Company | CENTER FOR CLINICAL STUDIES LTD LLP | $7,719 | A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITI | 2025 |
| 2025-10-13 | SUN PHARMACEUTICAL INDUSTRIES INC. | CENTER FOR CLINICAL STUDIES LTD LLP | $7,472 | Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis | 2025 |
| 2025-10-09 | ABBVIE INC. | CENTER FOR CLINICAL STUDIES LTD LLP | $6,998 | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Sever | 2025 |
| 2025-10-09 | SUN PHARMACEUTICAL INDUSTRIES INC. | CENTER FOR CLINICAL STUDIES LTD LLP | $6,046 | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Ps | 2025 |
| 2025-10-09 | Incyte Corporation | CENTER FOR CLINICAL STUDIES | $909 | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participa | 2025 |
| 2025-10-09 | ABBVIE INC. | CENTER FOR CLINICAL STUDIES LTD LLP | $2,538 | A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Mode | 2025 |
| 2025-10-08 | Novartis Pharmaceuticals Corporation | CENTER FOR CLINICAL STUDIES | $216 | A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared | 2025 |
| 2025-10-03 | Incyte Corporation | CENTER FOR CLINICAL STUDIES | $78 | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participa | 2025 |
| 2025-10-03 | Incyte Corporation | CENTER FOR CLINICAL STUDIES | $212 | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participa | 2025 |
| 2025-10-03 | Incyte Corporation | CENTER FOR CLINICAL STUDIES | $1,100 | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participa | 2025 |
| 2025-10-03 | Incyte Corporation | CENTER FOR CLINICAL STUDIES | $1,946 | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | 2025 |
| 2025-09-29 | Janssen Research & Development, LLC | CENTER FOR CLINICAL STUDIES LTD LLP | $1,262 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Stu | 2025 |
| 2025-09-29 | Janssen Research & Development, LLC | CENTER FOR CLINICAL STUDIES LTD LLP | $12,326 | A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Ef | 2025 |
| 2025-09-26 | Janssen Research & Development, LLC | CENTER FOR CLINICAL STUDIES LTD LLP | $114 | A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Ef | 2025 |
| 2025-09-24 | PFIZER INC. | CENTER FOR CLINICAL STUDIES LTD LLP | $12,965 | A PHASE 3 EXTERNAL AND SYNTHETIC PLACEBOCONTROLLED RANDOMIZED STUDY WITH DOSEUP FOR NONRESPONDERS TO INVESTIGATE SAFETY | 2025 |
| 2025-09-23 | Incyte Corporation | CENTER FOR CLINICAL STUDIES | $360 | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participa | 2025 |
| 2025-09-19 | PFIZER INC. | Center for Clinical Studies LTDLLP | $4,883 | A PHASE 3 RANDOMIZED DOUBLEBLIND 52WEEK PLACEBOCONTROLLED MULTICENTER STUDY WITH A DOUBLEBLIND 52WEEK EXTENSION PERIOD W | 2025 |
| 2025-09-18 | Incyte Corporation | CENTER FOR CLINICAL STUDIES | $4,131 | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participa | 2025 |
| 2025-09-08 | Janssen Research & Development, LLC | CENTER FOR CLINICAL STUDIES LTD LLP | $2,509 | A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Ef | 2025 |
| 2025-09-08 | Eli Lilly and Company | CENTER FOR CLINICAL STUDIES LTD LLP | $2,000 | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, OPERATIONALLY SEAMLESS, ADAPTIVE PHASE 2/3 STUDY TO EVALUAT | 2025 |
| 2025-09-04 | ABBVIE INC. | CENTER FOR CLINICAL STUDIES LTD LLP | $13,877 | A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Sever | 2025 |
| 2025-09-04 | Janssen Research & Development, LLC | CENTER FOR CLINICAL STUDIES LTD LLP | $1,262 | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-772 | 2025 |
| 2025-09-04 | Incyte Corporation | CENTER FOR CLINICAL STUDIES | $275 | A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1) | 2025 |
| 2025-09-04 | Incyte Corporation | CENTER FOR CLINICAL STUDIES | $1,702 | A Phase 3, Randomized, Double-Blind, 52-Week, Placebo-Controlled, Efficacy and Safety Study of Povorcitinib in Participa | 2025 |
| 2025-09-03 | SANOFI US SERVICES INC. | CENTER FOR CLINICAL STUDIES LTD LLP | $1,300 | A Phase 2, Randomized, Double-blind, Placebo-controlled, Parallel Group, Proof-of-concept Study Assessing the Efficacy a | 2025 |
| 2025-09-03 | ABBVIE INC. | CENTER FOR CLINICAL STUDIES LTD LLP | $7,195 | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participant | 2025 |
| 2025-09-03 | ABBVIE INC. | CENTER FOR CLINICAL STUDIES LTD LLP | $532 | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Sc | 2025 |
| 2025-09-03 | ABBVIE INC. | CENTER FOR CLINICAL STUDIES LTD LLP | $1,835 | A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Sever | 2025 |
| 2025-08-29 | Janssen Research & Development, LLC | CENTER FOR CLINICAL STUDIES LTD LLP | $3,468 | A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Ef | 2025 |
| 2025-08-27 | SUN PHARMACEUTICAL INDUSTRIES INC. | CENTER FOR CLINICAL STUDIES LTD LLP | $895 | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Ps | 2025 |
| 2025-08-26 | ABBVIE INC. | CENTER FOR CLINICAL STUDIES LTD LLP | $2,816 | Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Sc | 2025 |
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Webster, TX, county Harris County, TX, state Texas; placed by its city name.
| Measure | Place (city or town) Webster, TX | County Harris County, TX | State Texas |
|---|---|---|---|
| Population B01003 | 12,366 | 4,838,303 | 30,188,424 |
| Population, 2020 census P1 | 12,499 | 4,731,145 | 29,145,505 |
| Median age B01002 | 33.3 | 34.6 | 35.6 |
| Under 18 B01001 | 19.6% | 25.9% | 25.0% |
| 65 and over B01001 | 14.7% | 11.7% | 13.4% |
| Households B11001 | 5,991 | 1,757,164 | 10,992,816 |
| Foreign born B05002 | 18.2% | 26.8% | 17.6% |
| Median household income B19013 | $61,264 | $74,983 | $78,476 |
| Median family income B19113 | $80,041 | $88,512 | $94,599 |
| Per capita income B19301 | $41,153 | $41,006 | $40,752 |
| Poverty rate B17001 | 13.7% | 16.3% | 13.8% |
| Unemployment rate B23025 | 6.5% | 6.7% | 5.3% |
| Civilian labor force B23025 | 7,172 | 2,512,311 | 15,233,563 |
| Mean commute (minutes) B08013 | 27.8 | 29.0 | 26.7 |
| Bachelor's degree or higher B15003 | 37.9% | 34.2% | 33.8% |
| Housing units B25001 | 6,641 | 1,917,790 | 12,128,515 |
| Owner-occupied B25003 | 22.4% | 54.7% | 62.6% |
| Renters B25003 | 77.6% | 45.3% | 37.4% |
| Median home value B25077 | $281,400 | $276,600 | $283,800 |
| Median gross rent B25064 | $1,393 | $1,401 | $1,403 |
| White, not Hispanic B03002 | 44.9% | 26.6% | 39.1% |
| Black B03002 | 16.9% | 18.6% | 11.9% |
| Hispanic or Latino B03002 | 27.4% | 44.0% | 39.7% |
| Asian B03002 | 7.1% | 7.3% | 5.5% |
| American Indian and Alaska Native B03002 | 0.0% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Webster, TX.
Comments